Drug Interactions between Aptivus and givinostat
This report displays the potential drug interactions for the following 2 drugs:
- Aptivus (tipranavir)
- givinostat
Interactions between your drugs
tipranavir givinostat
Applies to: Aptivus (tipranavir) and givinostat
MONITOR: Givinostat may increase the concentration of CYP450 3A4 substrates via inhibition of the isoenzyme. Givinostat appears to be a weak inhibitor of intestinal CYP450 3A4, but not a significant inhibitor or inducer of hepatic CYP450 3A4; hence, the interaction may be more significant for orally administered CYP450 3A4 substrates. A pharmacokinetic study conducted in healthy volunteers (n=26) found that the peak plasma concentration (Cmax) and systemic exposure (AUC) of a single dose of oral midazolam (2.5 mg) increased from baseline after 3 days of givinostat oral suspension (50 mg twice daily) by 24% and 39%, respectively. After 14 days of coadministration, the Cmax and AUC of oral midazolam had increased by 39% and 67%, respectively. When oral givinostat was studied in combination with intravenous midazolam, only a very slight increase in midazolam's AUC was observed.
MANAGEMENT: Caution and clinical monitoring are advised if givinostat is used in combination with an orally administered CYP450 3A4 sensitive substrate for which a small change in substrate plasma concentration could lead to serious toxicities. The labeling of the substrate should be consulted for specific monitoring, dose adjustment, and discontinuation recommendations should adverse reactions result from this combination.
References (2)
- (2024) "Product Information. Duvyzat (givinostat)." ITF Therapeutics, LLC
- Italfarmaco Spa (2024) Center for drug evaluation and research. Application number: 217865Orig1s000. Integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217865Orig1s000IntegratedR.pdf
Drug and food interactions
tipranavir food
Applies to: Aptivus (tipranavir)
ADJUST DOSING INTERVAL: Food does not appear to substantially alter the pharmacokinetics of tipranavir. When tipranavir capsules or oral solution was coadministered with ritonavir capsules at steady-state, no clinically significant changes in tipranavir peak plasma concentration (Cmax) and systemic exposure (AUC) were observed under fed conditions (500 to 682 kcal, 23% to 25% calories from fat) relative to fasted conditions. The effect of food on tipranavir exposure during coadministration with ritonavir tablets has not been evaluated. High-fat foods may enhance the gastrointestinal absorption of tipranavir. In a multiple-dose study, administration of tipranavir capsules with a high-fat meal (868 kcal, 53% from fat, 31% from carbohydrates) increased the oral bioavailability of tipranavir by 31% compared to administration with toast and skimmed milk, but did not significantly affect tipranavir Cmax. Thus, tipranavir may be safely taken with standard or high-fat meals.
MANAGEMENT: Tipranavir coadministered with low-dose ritonavir should be taken with food to improve the gastrointestinal tolerability of ritonavir. According to the product labeling, tipranavir coadministered with ritonavir capsules or solution can be taken with or without meals, whereas tipranavir coadministered with ritonavir tablets must be taken with meals.
References (4)
- (2005) "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
- Cerner Multum, Inc. "Australian Product Information."
givinostat food
Applies to: givinostat
ADJUST DOSING INTERVAL: Food increases the systemic exposure of givinostat. An open-label, randomized, crossover, single dose food effect study conducted in 12 healthy males used givinostat liquid filled capsules. Subjects received a single oral dose of givinostat (100 mg) in the fasting state or after a high-fat standard meal, with a washout period of at least 1 week in between. The high-fat standard meal resulted in an increase in systemic exposure (AUC) and maximum plasma concentration (Cmax) of about 40% and 23%, respectively, when compared to the fasted state. Additionally, the time to maximum concentration (Tmax) was delayed slightly from 2 to 3 hours.
MANAGEMENT: Givinostat should be administered with food to increase its absorption. In the case of the oral suspension, this can also help mask its bitter taste.
References (2)
- (2024) "Product Information. Duvyzat (givinostat)." ITF Therapeutics, LLC
- Italfarmaco Spa (2024) Center for drug evaluation and research. Application number: 217865Orig1s000. Integrated review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/217865Orig1s000IntegratedR.pdf
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.